4-hydrazinyl-6-methylpyrimidine | 33592-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-hydrazinyl-6-methylpyrimidine
• 英文别名: 4-hydrazine-6-methylpyrimidine；4-hydrazino-6-methyl-pyrimidine；(6-methyl-pyrimidin-4-yl)-hydrazine；(6-Methyl-pyrimidin-4-yl)-hydrazin；(6-methylpyrimidin-4-yl)hydrazine
• CAS: 33592-43-7
• 化学式: C₅H₈N₄
• mdl: MFCD12403875
• 分子量: 124.145
• InChiKey: QZWHXGZANIHORL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydrazinyl-6-methylpyrimidine 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 8.0h， 生成 (Z)-N-(1-(1H-tetrazol-5-yl)prop-1-en-2-yl)formamide
  参考文献：
  名称：

  [EN] CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF
  [FR] COMPOSITIONS CHIMIQUES PARTICULIÈRES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开提供了CDK9抑制剂。还提供了治疗疾病或紊乱的方法，包括向需要治疗的受试者施用本公开的CDK9抑制剂之一。在某些实施例中，要治疗的疾病或紊乱是癌症。在某些实施例中，疾病或紊乱是肝癌。

  公开号：

  WO2021231892A1
• 作为产物：
  描述：

  4-氯-6-甲基嘧啶 在 potassium carbonate 、 一水合肼 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.0h， 生成 4-hydrazinyl-6-methylpyrimidine
  参考文献：
  名称：

  [EN] CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF
  [FR] COMPOSITIONS CHIMIQUES PARTICULIÈRES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开提供了CDK9抑制剂。还提供了治疗疾病或紊乱的方法，包括向需要治疗的受试者施用本公开的CDK9抑制剂之一。在某些实施例中，要治疗的疾病或紊乱是癌症。在某些实施例中，疾病或紊乱是肝癌。

  公开号：

  WO2021231892A1

文献信息

• Gabriel; Colman, Chemische Berichte, 1901, vol. 34, p. 1242
  作者：Gabriel、Colman

  DOI：——

  日期：——
• Azinyl and Diazinyl Hydrazones Derived from Aryl <i>N</i>-Heteroaryl Ketones:  Synthesis and Antiproliferative Activity^,
  作者：Johnny Easmon、Gottfried Heinisch、Gerhard Pürstinger、Thierry Langer、Jürgen K. Österreicher、Hans H. Grunicke、Johann Hofmann

  DOI：10.1021/jm970255w

  日期：1997.12.1

  A series of N-heteroaryl hydrazones derived from aryl N-heteroaryl or bis-N-heteroaryl methanones was prepared in search for potential novel antitumor agents. The stereochemistry of these compounds was established by means of NMR spectroscopy. Antiproliferative activity was determined in a panel of human tumor cell Lines (CCRF-CEM, Burkitt's lymphoma, HeLa, ZR-75-1, HT-29, and MEXF 276L) in vitro. Generally, the new compounds were found to be more patent (IC(50) = 0.011-0.436 mu M) than the ribonucleotide reductase inhibitor hydroxyurea (IC(50) = 140 mu M) Most of the compounds exhibited the highest activity against Burkitt's lymphoma with an IC(50) Of 0.011-0.035 mu M. [(14)C]Cytidine incorporation into DNA was quantitated for selected hydrazones (Z-A, E-1, Z-3, Z-4, E-5, Z-5, E-13, E-18, Z-19, Z-24, and E-26) as a measure of the inhibition of-ribonucleotide reductase in Burkitt's lymphoma cells. The E-configurated compounds were found to inhibit [(14)C]cytidine incorporation to a greater extent (IC(50) = 0.67-5.05 mu M) than the Z-isomers (IC(50) = 7.20 to > 10 mu M). Principal component analysis of the IC(50) values obtained for inhibition of cell proliferation revealed that the cell lines tested can be grouped into three main families showing different sensitivities toward the compounds in our series [(i) CCRF-CEM, Burkitt's lymphoma, and Hela; (ii) HT-29; and (iii) MEXF 276 L].
• 141. The preparation of fused triazole systems
  作者：J. D. Bower、F. P. Doyle

  DOI：10.1039/jr9570000727

  日期：——
• Claesen; Vanderhaeghe, Bulletin des Societes Chimiques Belges, 1959, vol. 68, p. 47,49,57
  作者：Claesen、Vanderhaeghe

  DOI：——

  日期：——
• Shiho; Takahayashi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 773
  作者：Shiho、Takahayashi

  DOI：——

  日期：——